Entries by Katja Buhrer

Kindred Biosciences Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates

October 7, 2020 in , , /by

San Francisco, California (October 7, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has expanded an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine for COVID-19 and other vaccine candidates. The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a […]

Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody

September 16, 2020 in , , /by

Study demonstrated 100% efficacy in prevention of parvovirus infection in prophylactic pivotal study of KIND-030 San Francisco, California (September 16, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine […]

Kindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference and Lake Street Best Ideas Growth Conference

September 9, 2020 in , , /by

SAN FRANCISCO, September 9, 2020 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 14-15, the Cantor Global Healthcare Conference on September 16, and the Lake Street Best Ideas Growth Conference on September 17.   Dr. Richard Chin, […]

Kindred Biosciences Announces Plan to Strengthen its Strategic Position

June 8, 2020 in , , /by

San Francisco, California (June 8, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to enhance its strategic position. The company will prioritize its most attractive late stage programs and substantially reduce expenses to best position it for success with the […]